Drug Discovery World

AUGUST 16, 2023

Samir Ounzain , PhD, CEO & Co-Founder of HAYA Therapeutics, looks at how a better understanding of our DNA can lead to increased activity for RNA therapeutics. The whole world realised the power of RNA when the Covid-19 pandemic brought us the first mRNA-based vaccines.

RNA 52

RNA Genome Genomics DNA 52

pharmaphorum

JANUARY 26, 2023

We are already seeing an increase in projects exploring population genomics in Africa, the Middle East, and Asia, with initiatives including the GenomeAsia100K Project and the Genome Aggregation Database focusing on capturing genetic data of non-European individuals.

Genome 115

Genome Genomics Genome Project Genetics 115

Drug Discovery World

JULY 17, 2024

A global collaboration led by scientists at the University of Oxford has discovered that genetic variants in a specific gene cause a rare neurodevelopmental disorder (NDD). This discovery was initially made using data from the 100,000 Genomes Project, a study led by Genomics England and NHS England.

Genetics 52

Genetics Genome Project Genome Genomics 52

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Drug Discovery World

OCTOBER 6, 2022

Both the binary and quantitative have relied on measurement of protein, DNA, and more recently, RNA. He is the founder and CEO of Cofactor Genomics, a diagnostic company leveraging the power of RNA and machine learning to build disease models.

Medicine 52

Medicine Clinical Trials Clinical Trials Genome 52